AbstractHeartfailure(HF) is a growing public health concern, driven by the increasing prevalence of obesity, diabetes, and aging. Despite therapeutic advances, HF continues to be associated with high morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for glycemic control in type 2 diabetes, have demonstrated cardiovascular benefits in ...
Several glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to reduce major adverse cardiovascular events among patients with type 2 diabetes (T2D).1While pooling of trial data demonstrated beneficial effects ofGLP-1RAs onheartfailure(HF) outcomes in populations with T2D, their effects across different HF subtypes (ie, reduced vs preserved ejection fraction) are less ...
GLP-1receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital forheartfailure.
Quick Takes Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond diabetes mellitus management, guided by the latest clinical trial findings and guidelines. Clinicians should be vigilant for gastrointestinal tract adverse effects in patients using ...
Moving forward, it's essential to keep these visual contexts in mind when discussing Glp-1 Therapy And Heart Failure Prevention.
Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated significant cardiometabolic benefits, particularly in patients with type 2 diabetes and obesity. Their role inheartfailure(HF) is gaining increasing attention, with growing evidence supporting their efficacy in HF with preserved ejection fraction (HFpEF). Recent trials have shown that semaglutide improves symptoms ...
